
64.04 Delayed Data As of Mar 01 | ![]() Today’s Change | 9.18 Today|||52-Week Range 92.00 | +17.72% Year-to-Date |
Intellia (NTLA) Miss Earnings & Revenues Estimates in Q4 Feb 26 / Zacks.com - Paid Partner Content | Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar? Feb 19 / Zacks.com - Paid Partner Content |
Intellia Therapeutics, Inc. (NTLA) Q4 2020 Earnings Call Transcript Feb 25 / MotleyFool.com - Paid Partner Content | Will Intellia Therapeutics, Inc. (NTLA) Report Negative Q4 Earnings? What You Should Know Feb 18 / Zacks.com - Paid Partner Content |
Will Editas Medicine's CEO Change Help or Hurt? Feb 20 / MotleyFool.com - Paid Partner Content | Where Will Editas Medicine Be in 5 Years? Feb 17 / MotleyFool.com - Paid Partner Content |
Previous close | 60.46 |
Today’s open | 61.50 |
Day’s range | 61.39 - 67.94 |
Volume | 1,566,506 |
Average volume (3 months) | 1,508,059 |
Market cap | $3.6B |
Earnings growth (last year) | -13.81% |
Earnings growth (this year) | -20.67% |
Earnings growth (next 5 years) | -- |
Revenue growth (last year) | +34.55% |
P/E ratio | NM |
Price/Sales | 52.52 |
Price/Book | -- |
Today’s change | Today’s % change | |
---|---|---|
NKNantKwest Inc | +0.79 | +2.43% |
ARVNArvinas Inc | -1.00 | -1.28% |
RCKTRocket Pharmaceutica... | +0.16 | +0.29% |
MORMorphoSys AG | +0.51 | +2.05% |
Next reporting date | May 4, 2021 |
EPS forecast (this quarter) | -$0.69 |
Annual revenue (last year) | $58.0M |
Annual profit (last year) | -$134.2M |
Net profit margin | -231.46% |
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |